{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:31:05Z","timestamp":1780392665993,"version":"3.54.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Clinics of North America: Small Animal Practice"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.cvsm.2010.07.006","type":"journal-article","created":{"date-parts":[[2010,10,8]],"date-time":"2010-10-08T08:43:27Z","timestamp":1286527407000},"page":"1171-1188","source":"Crossref","is-referenced-by-count":53,"title":["Antifungal Treatment of Small Animal Veterinary Patients"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniel S.","family":"Foy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Trepanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccm.2009.02.001","article-title":"Overview of antifungal agents","volume":"30","author":"Thompson","year":"2009","journal-title":"Clin Chest Med"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib3","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1086\/507891","article-title":"New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage","volume":"43","author":"Spanakis","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1345\/aph.1L005","article-title":"Posaconazole: an oral triazole with an extended spectrum of activity","volume":"42","author":"Rachwalski","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev"},{"issue":"3-4","key":"10.1016\/j.cvsm.2010.07.006_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0304-4157(86)90002-X","article-title":"How do the polyene macrolide antibiotics affect the cellular membrane properties?","volume":"864","author":"Bolard","year":"1986","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jac\/33.2.203","article-title":"Administering amphotericin B\u2013a practical approach","volume":"33","author":"Khoo","year":"1994","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00075198-200112000-00002","article-title":"Can we decrease amphotericin nephrotoxicity?","volume":"7","author":"Costa","year":"2001","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-3565(25)32172-5","article-title":"The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity","volume":"214","author":"Gerkens","year":"1980","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib11","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1172\/JCI115240","article-title":"Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats","volume":"87","author":"Sawaya","year":"1991","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib12","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/AAC.33.8.1222","article-title":"Sodium status influences chronic amphotericin B nephrotoxicity in rats","volume":"33","author":"Ohnishi","year":"1989","journal-title":"Antimicrobial Agents Chemother"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/14656566.4.8.1277","article-title":"The lipid formulations of amphotericin B","volume":"4","author":"Herbrecht","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 2","key":"10.1016\/j.cvsm.2010.07.006_bib15","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1399-3062.1999.010406.x","article-title":"Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability","volume":"1","author":"Tiphine","year":"1999","journal-title":"Transpl Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cvsm.2010.07.006_bib17","first-page":"35","article-title":"Liposomal amphotericin B, AmBisome","volume":"28","author":"Hay","year":"1994","journal-title":"J\u00a0Infect"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jac\/33.5.907","article-title":"Clinical use of liposomal and lipid\u2013complexed amphotericin B","volume":"33","author":"de Marie","year":"1994","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.cvsm.2010.07.006_bib19","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler-Moore","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.cvsm.2010.07.006_bib20","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1023\/A:1018997730462","article-title":"Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs","volume":"16","author":"Bekersky","year":"1999","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.26.4.446","article-title":"Comparative pharmacokinetics of SCH 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys","volume":"26","author":"Kim","year":"1984","journal-title":"Antimicrobial Agents Chemother"},{"issue":"16","key":"10.1016\/j.cvsm.2010.07.006_bib22","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.85.16.6122","article-title":"Unusual lipid structures selectively reduce the toxicity of amphotericin B","volume":"85","author":"Janoff","year":"1988","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.cvsm.2010.07.006_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.2042-7158.1991.tb03189.x","article-title":"Tissue distribution of amphotericin B lipid complex in laboratory animals","volume":"43","author":"Olsen","year":"1991","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib24","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.44.10.2900-2902.2000","article-title":"A\u00a0pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections","volume":"44","author":"Adedoyin","year":"2000","journal-title":"Antimicrobial Agents Chemother"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.42.4.767","article-title":"In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?","volume":"42","author":"Swenson","year":"1998","journal-title":"Antimicrobial Agents Chemother"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/08982109309150730","article-title":"Amphotericin B lipid complex (ABLC\u2122):a molecular rationale for the attenuation of amphotericin B related toxicities","volume":"3","author":"Janoff","year":"1993","journal-title":"J\u00a0Liposome Res"},{"issue":"12","key":"10.1016\/j.cvsm.2010.07.006_bib27","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2460\/javma.1996.209.12.2073","article-title":"Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs","volume":"209","author":"Krawiec","year":"1996","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"Suppl 2","key":"10.1016\/j.cvsm.2010.07.006_bib28","first-page":"s93","article-title":"Liposomal and lipid-based formulations of amphotericin B","volume":"10","author":"de Marie","year":"1996","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.cvsm.2010.07.006_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000048472","article-title":"Safety and efficacy of amphotericin B colloidal dispersion. An overview","volume":"45","author":"Herbrecht","year":"1999","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/AAC.36.2.299","article-title":"Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs","volume":"36","author":"Fielding","year":"1992","journal-title":"Antimicrobial Agents Chemother"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"A\u00a0systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","article-title":"Effect of salt supplementation on amphotericin B nephrotoxicity","volume":"40","author":"Llanos","year":"1991","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00467-008-1050-4","article-title":"Influence of sodium intake on amphotericin B-induced nephrotoxicity among extremely premature infants","volume":"24","author":"Turcu","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib35","first-page":"313","article-title":"Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care?","volume":"162","author":"Anderson","year":"1995","journal-title":"West J Med"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MOH.0b013e328311890c","article-title":"Invasive aspergillosis: diagnosis, prophylaxis and treatment","volume":"15","author":"Del Bono","year":"2008","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0891-5520(20)30232-4","article-title":"Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis","volume":"2","author":"Knoper","year":"1988","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cvsm.2010.07.006_bib38","first-page":"1086","article-title":"Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis","volume":"49","author":"Kotwani","year":"2001","journal-title":"J\u00a0Assoc Physicians India"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1378\/chest.93.4.848","article-title":"Treatment of histoplasmosis and blastomycosis","volume":"93","author":"Saag","year":"1988","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1164\/arrd.1982.125.5.610","article-title":"Amphotericin B in liposomes: a novel therapy for histoplasmosis","volume":"125","author":"Taylor","year":"1982","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2460\/javma.1998.213.05.658","article-title":"Blastomycosis in dogs: 115 cases (1980\u20131995)","volume":"213","author":"Arceneaux","year":"1998","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5326\/0440226","article-title":"Coccidioidomycosis in dogs and cats: a review","volume":"44","author":"Graupmann-Kuzma","year":"2008","journal-title":"J\u00a0Am Anim Hosp Assoc"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib43","first-page":"95","article-title":"Disseminated canine histoplasmosis: a clinical survey of 24 cases in Texas","volume":"21","author":"Mitchell","year":"1980","journal-title":"Can Vet J"},{"issue":"11","key":"10.1016\/j.cvsm.2010.07.006_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1751-0813.2006.00040.x","article-title":"Long-term outcome of therapy for 59 cats and 11 dogs with cryptococcosis","volume":"84","author":"O\u2019Brien","year":"2006","journal-title":"Aust Vet J"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1939-1676.2008.0125.x","article-title":"Clinicopathologic and diagnostic imaging characteristics of systemic aspergillosis in 30 dogs","volume":"22","author":"Schultz","year":"2008","journal-title":"J\u00a0Vet Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.cvsm.2010.07.006_bib46","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1093\/clinids\/22.Supplement_2.S148","article-title":"Role of azoles in antifungal therapy","volume":"22","author":"Kauffman","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0966-842X(97)01206-7","article-title":"Emerging targets for the development of novel antifungal therapeutics","volume":"6","author":"Groll","year":"1998","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-2008-1063858","article-title":"Update on azole antifungals","volume":"29","author":"Zonios","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","article-title":"Oral azole drugs as systemic antifungal therapy","volume":"330","author":"Como","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cvsm.2010.07.006_bib51","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00003088-200140110-00004","article-title":"Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions","volume":"40","author":"Pea","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11095-004-1185-3","article-title":"pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model","volume":"22","author":"Zhou","year":"2005","journal-title":"Pharm Res"},{"issue":"6 (Pt 1)","key":"10.1016\/j.cvsm.2010.07.006_bib53","first-page":"861","article-title":"Results of a prospective randomized clinical trial. National institute of allergy and infectious diseases mycoses study group","volume":"103","author":"Treatment of blastomycosis and histoplasmosis with ketoconazole","year":"1985","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.cvsm.2010.07.006_bib54","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2460\/javma.1988.193.11.1443","article-title":"Disseminated histoplasmosis in dogs: 12 cases (1981\u20131986)","volume":"193","author":"Clinkenbeard","year":"1988","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1939-1676.1994.tb03260.x","article-title":"Itraconazole for the treatment of histoplasmosis in cats","volume":"8","author":"Hodges","year":"1994","journal-title":"J\u00a0Vet Intern Med"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1939-1676.1996.tb02082.x","article-title":"Treatment of blastomycosis with itraconazole in 112 dogs","volume":"10","author":"Legendre","year":"1996","journal-title":"J\u00a0Vet Intern Med"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ctsap.2005.07.004","article-title":"Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats","volume":"20","author":"Bromel","year":"2005","journal-title":"Clin Tech Small Anim Pract"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.ctsap.2005.07.003","article-title":"Histoplasmosis in dogs and cats","volume":"20","author":"Bromel","year":"2005","journal-title":"Clin Tech Small Anim Pract"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3164.2008.00721.x","article-title":"Evidence-based veterinary dermatology: a systematic review of interventions for malassezia dermatitis in dogs","volume":"20","author":"Negre","year":"2009","journal-title":"Vet Dermatol"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-3164.2008.00675.x","article-title":"Adverse effects of ketoconazole in dogs\u2013a retrospective study","volume":"19","author":"Mayer","year":"2008","journal-title":"Vet Dermatol"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2460\/javma.1992.200.01.77","article-title":"Ketoconazole for treatment of dermatophytosis in cats","volume":"200","author":"Medleau","year":"1992","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"12","key":"10.1016\/j.cvsm.2010.07.006_bib62","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/106002809102501206","article-title":"Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis","volume":"25","author":"Brusko","year":"1991","journal-title":"DICP"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0300-483X(94)02911-D","article-title":"Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes","volume":"96","author":"Rodriguez","year":"1995","journal-title":"Toxicology"},{"issue":"2-3","key":"10.1016\/j.cvsm.2010.07.006_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0300-483X(96)03560-3","article-title":"N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes","volume":"117","author":"Rodriguez","year":"1997","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/0049825031000072243","article-title":"Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding","volume":"33","author":"Rodriguez","year":"2003","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib66","first-page":"311","article-title":"Multiple oral dosing of ketoconazole increases dog exposure to ivermectin","volume":"10","author":"Hugnet","year":"2007","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1124\/dmd.30.1.63","article-title":"Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs","volume":"30","author":"Kuroha","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1532-950X.1998.tb00099.x","article-title":"Effect of ketoconazole on cyclosporine dose in healthy dogs","volume":"27","author":"Dahlinger","year":"1998","journal-title":"Vet Surg"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib69","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1532-950X.1999.00448.x","article-title":"The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats","volume":"28","author":"McAnulty","year":"1999","journal-title":"Vet Surg"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/acta.0.1070275","article-title":"Endocrinological effects of single daily ketoconazole administration in male beagle dogs","volume":"107","author":"De Coster","year":"1984","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"12","key":"10.1016\/j.cvsm.2010.07.006_bib71","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2460\/javma.233.12.1896","article-title":"Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994\u20132007)","volume":"233","author":"Lien","year":"2008","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"Suppl 3","key":"10.1016\/j.cvsm.2010.07.006_bib72","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib73","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.2460\/ajvr.2001.62.1606","article-title":"Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses","volume":"62","author":"Latimer","year":"2001","journal-title":"Am J Vet Res"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2885.1997.tb00093.x","article-title":"Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid","volume":"20","author":"Vaden","year":"1997","journal-title":"J\u00a0Vet Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cvsm.2010.07.006_bib75","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/clinids\/14.Supplement_1.S68","article-title":"A\u00a0pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group","volume":"14","author":"Diaz","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib76","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/clinids\/20.2.267","article-title":"Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"20","author":"Pappas","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","article-title":"Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID mycoses study group and the AIDS clinical trials group","volume":"326","author":"Saag","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","article-title":"Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity","volume":"7","author":"Lim","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib79","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrobial Agents Chemother"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib80","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.2042-7158.1994.tb03777.x","article-title":"Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties","volume":"46","author":"Jezequel","year":"1994","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/02681219280000181","article-title":"Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole","volume":"30","author":"Malik","year":"1992","journal-title":"J\u00a0Med Vet Mycol"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib82","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/clinids\/22.2.336","article-title":"Fluconazole-induced congenital anomalies in three infants","volume":"22","author":"Pursley","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","article-title":"Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations","volume":"30","author":"Smith","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1099-1069(1998030)16:1<33::AID-HON620>3.0.CO;2-9","article-title":"Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole","volume":"16","author":"Kanda","year":"1998","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1939-1676.1997.tb00064.x","article-title":"Cryptococcal infection in cats: factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats","volume":"11","author":"Jacobs","year":"1997","journal-title":"J\u00a0Vet Intern Med"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib86","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2006.11.027","article-title":"Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance","volume":"30","author":"Pasqualotto","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib87","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/archinte.1989.00390100107024","article-title":"Itraconazole therapy for cryptococcal meningitis and cryptococcosis","volume":"149","author":"Denning","year":"1989","journal-title":"Arch Intern Med"},{"issue":"7\u20138","key":"10.1016\/j.cvsm.2010.07.006_bib88","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib89","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/21.1.93","article-title":"Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole","volume":"21","author":"Warnock","year":"1988","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7326\/0003-4819-113-4-327","article-title":"Cyclosporine and itraconazole interaction in heart and lung transplant recipients","volume":"113","author":"Kramer","year":"1990","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib91","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/clind\/16.3.400","article-title":"Interaction of itraconazole and digoxin","volume":"16","author":"Sachs","year":"1993","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib92","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib93","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib94","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199651040-00006","article-title":"Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections","volume":"51","author":"Haria","year":"1996","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.cvsm.2010.07.006_bib95","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1128\/AAC.42.7.1862","article-title":"Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers","volume":"42","author":"Barone","year":"1998","journal-title":"Antimicrobial Agents Chemother"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib96","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2460\/ajvr.1997.58.08.872","article-title":"Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats","volume":"58","author":"Boothe","year":"1997","journal-title":"Am J Vet Res"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib97","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib98","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib99","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","article-title":"In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum","volume":"44","author":"Li","year":"2000","journal-title":"Antimicrobial Agents Chemother"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib101","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1086\/376985","article-title":"Liver failure in a child receiving highly active antiretroviral therapy and voriconazole","volume":"37","author":"Scherpbier","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib102","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archneur.62.1.144","article-title":"Painful peripheral neuropathy associated with voriconazole use","volume":"62","author":"Tsiodras","year":"2005","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib103","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s10096-004-1176-7","article-title":"Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole","volume":"23","author":"Vandecasteele","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib104","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkp464","article-title":"Safety of triazole antifungal drugs in patients with cancer","volume":"65","author":"Cronin","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib106","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3314\/jjmm.50.091","article-title":"Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses","volume":"50","author":"Okabayashi","year":"2009","journal-title":"Nippon Ishinkin Gakkai Zasshi"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib107","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi","volume":"41","author":"Diekema","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib108","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib109","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/519937","article-title":"Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis","volume":"45","author":"Catanzaro","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib110","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J\u00a0Clin Microbiol"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib111","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrobial Agents Chemother"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib112","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib113","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib114","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1592\/phco.27.6.825","article-title":"Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus","volume":"27","author":"Sansone-Parsons","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib116","first-page":"854","article-title":"Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole","volume":"42","author":"Conte","year":"1992","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/vr.158.6.193","article-title":"Comparison of an antifungal agent with a mixture of antifungal, antibiotic and corticosteroid agents for the treatment of Malassezia species otitis in dogs","volume":"158","author":"Bensignor","year":"2006","journal-title":"Vet Rec"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib118","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ctsap.2005.12.015","article-title":"Canine nasal aspergillosis","volume":"21","author":"Benitah","year":"2006","journal-title":"Clin Tech Small Anim Pract"},{"issue":"5","key":"10.1016\/j.cvsm.2010.07.006_bib119","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.cvsm.2007.05.005","article-title":"Update on canine sinonasal aspergillosis","volume":"37","author":"Peeters","year":"2007","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib120","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2460\/javma.235.10.1188","article-title":"Intranasal infusion of clotrimazole for the treatment of nasal aspergillosis in two cats","volume":"235","author":"Furrow","year":"2009","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib121","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2460\/javma.2003.222.1380","article-title":"Fungal rhinitis and sinusitis in three cats","volume":"222","author":"Tomsa","year":"2003","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib122","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2460\/javma.1998.213.04.501","article-title":"Comparison of topical administration of clotrimazole through surgically placed versus nonsurgically placed catheters for treatment of nasal aspergillosis in dogs: 60 cases (1990-1996)","volume":"213","author":"Mathews","year":"1998","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5326\/0430033","article-title":"Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole","volume":"43","author":"Schuller","year":"2007","journal-title":"J\u00a0Am Anim Hosp Assoc"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib124","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2460\/javma.2002.221.1421","article-title":"Intranasal infusion of enilconazole for treatment of sinonasal aspergillosis in dogs","volume":"221","author":"Zonderland","year":"2002","journal-title":"J\u00a0Am Vet Med Assoc"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5326\/15473317-33-3-264","article-title":"Upper-airway obstruction and prolonged recovery from anesthesia following intranasal clotrimazole administration","volume":"33","author":"Caulkett","year":"1997","journal-title":"J\u00a0Am Anim Hosp Assoc"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib126","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib127","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14728214.11.2.231","article-title":"Emerging echinocandins for treatment of invasive fungal infections","volume":"11","author":"Turner","year":"2006","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.27.3.369","article-title":"The echinocandins","volume":"27","author":"Cappelletty","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/589305","article-title":"Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae","volume":"198","author":"Lamaris","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","article-title":"In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi","volume":"44","author":"Tawara","year":"2000","journal-title":"Antimicrobial Agents Chemother"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib131","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.47.4.1376-1381.2003","article-title":"In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms","volume":"47","author":"Nakai","year":"2003","journal-title":"Antimicrobial Agents Chemother"},{"issue":"8","key":"10.1016\/j.cvsm.2010.07.006_bib132","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/501020","article-title":"Micafungin: a new echinocandin","volume":"42","author":"Chandrasekar","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.cvsm.2010.07.006_bib133","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrobial Agents Chemother"},{"issue":"10","key":"10.1016\/j.cvsm.2010.07.006_bib134","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A\u00a0randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"issue":"16","key":"10.1016\/j.cvsm.2010.07.006_bib136","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1517\/14656560903307462","article-title":"Terbinafine: a pharmacological and clinical review","volume":"10","author":"Krishnan-Natesan","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib137","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0738-081X(91)90077-X","article-title":"Terbinafine: an oral and topical antifungal agent","volume":"9","author":"Shear","year":"1991","journal-title":"Clin Dermatol"},{"issue":"Suppl 39","key":"10.1016\/j.cvsm.2010.07.006_bib138","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","article-title":"Terbinafine: mode of action and properties of the squalene epoxidase inhibition","volume":"126","author":"Ryder","year":"1992","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.cvsm.2010.07.006_bib139","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/000155557300304","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks","volume":"73","author":"Faergemann","year":"1993","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.cvsm.2010.07.006_bib140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00003495-199958010-00018","article-title":"Terbinafine. An update of its use in superficial mycoses","volume":"58","author":"McClellan","year":"1999","journal-title":"Drugs"},{"issue":"5\u20136","key":"10.1016\/j.cvsm.2010.07.006_bib141","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11046-008-9109-0","article-title":"Update in antifungal therapy of dermatophytosis","volume":"166","author":"Gupta","year":"2008","journal-title":"Mycopathologia"},{"issue":"2","key":"10.1016\/j.cvsm.2010.07.006_bib142","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/mmy.40.2.179.183","article-title":"In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin","volume":"40","author":"Hofbauer","year":"2002","journal-title":"Med Mycol"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-3164.2003.00334.x","article-title":"Comparative efficacies of oral ketoconazole and terbinafine for reducing Malassezia population sizes on the skin of Basset Hounds","volume":"14","author":"Guillot","year":"2003","journal-title":"Vet Dermatol"},{"issue":"3","key":"10.1016\/j.cvsm.2010.07.006_bib144","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-3164.2005.00455.x","article-title":"Comparison of the clinical efficacy of oral terbinafine and ketoconazole combined with cephalexin in the treatment of Malassezia dermatitis in dogs\u2013a pilot study","volume":"16","author":"Rosales","year":"2005","journal-title":"Vet Dermatol"}],"container-title":["Veterinary Clinics of North America: Small Animal Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195561610000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195561610000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T15:07:38Z","timestamp":1740582458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195561610000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0195561610000938"],"URL":"https:\/\/doi.org\/10.1016\/j.cvsm.2010.07.006","relation":{},"ISSN":["0195-5616"],"issn-type":[{"value":"0195-5616","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}